AngioDynamics (ANGO) 10-Q 10 Oct 13 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Aug. 31, 2013	Oct. 01, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Aug-13
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	1275187
Current Fiscal Year End Date	-26
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,253,222

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Income Statement [Abstract]
Net sales	$83,579	$83,406
Cost of sales	41,097	43,947
Gross profit	42,482	39,459
Operating expenses
Research and development	6,709	7,074
Sales and marketing	19,963	18,543
General and administrative	6,528	6,899
Amortization of intangibles	4,284	3,737
Change in fair value of contingent consideration	733
Acquisition, restructuring and other items, net	2,002	2,522
Medical device excise tax	976
Total operating expenses	41,195	38,775
Operating income	1,287	684
Other income (expenses)
Interest expense	-1,246	-1,332
Interest income		82
Other expense	-688	-588
Total other income (expenses)	-1,934	-1,838
Loss before income tax benefit	-647	-1,154
Income tax benefit	-221	-433
Net loss	($426)	($721)
Loss per share
Basic	($0.01)	($0.02)
Diluted	($0.01)	($0.02)
Basic weighted average shares outstanding	34,950	34,704
Diluted weighted average shares outstanding	34,950	34,704

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]
Net loss	($426)	($721)
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on interest rate swap	319	-1,088
Unrealized gain on marketable securities		33
Foreign currency translation gain	70	41
Other comprehensive income (loss), before tax	389	-1,014
Income tax (expense) benefit related to items of other comprehensive income	-118	391
Other comprehensive income (loss), net of tax	271	-623
Total comprehensive loss, net of tax	($155)	($1,344)

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Aug. 31, 2013	31-May-13
In Thousands, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$22,065	$21,802
Marketable securities, at fair value	1,850	2,153
Total cash, cash equivalents marketable securities	23,915	23,955
Accounts receivable, net of allowances of $1,467 and $1,272 respectively	46,561	47,791
Inventories	59,249	55,062
Deferred income taxes	6,516	6,591
Prepaid expenses and other	8,993	8,117
Total current assets	145,234	141,516
PROPERTY, PLANT AND EQUIPMENT-AT COST, net	63,748	62,650
OTHER ASSETS	5,307	5,559
INTANGIBLE ASSETS, net	216,355	214,848
GOODWILL	359,736	355,458
DEFERRED INCOME TAXES, long term	10,227	11,007
PREPAID ROYALTIES	546	546
TOTAL ASSETS	801,153	791,584
CURRENT LIABILITIES
Accounts payable	26,701	24,522
Accrued liabilities	16,499	16,426
Current portion of long-term debt	13,125	7,500
Current portion of contingent consideration	12,704	9,207
Other current liabilities	5,334	5,782
Total current liabilities	74,363	63,437
LONG-TERM DEBT, net of current portion	129,375	135,000
DEFERRED INCOME TAXES, long term	1,201
Contingent consideration, net of current portion	67,096	65,842
Other long term liabilities	673	475
Total liabilities	272,708	264,754
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued and outstanding 35,230,433 and 35,060,351 shares at August 31,2013, 2013 and May 31, 2013, respectively	352	351
Additional paid-in capital	502,323	500,554
Retained earnings	29,137	29,563
Treasury stock, 142,305 shares, at cost	-2,104	-2,104
Accumulated other comprehensive loss	-1,263	-1,534
Total stockholders' equity	528,445	526,830
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$801,153	$791,584

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2013	31-May-13
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Accounts receivable, allowances	$1,467	$1,272
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	35,230,433	35,060,351
Common stock, shares outstanding	35,230,433	35,060,351
Treasury stock, shares	142,305	142,305

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Cash flows from operating activities:
Net loss	($426)	($721)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	6,097	5,869
Stock based compensation	1,152	1,122
Change in fair value of contingent consideration	733
Deferred income taxes	538	-85
Change in accounts receivable allowances	195	-35
Tax effect on exercise of stock options and issuance of performance shares	-61
Other	-47	45
Amortization of acquired inventory basis step-up		3,445
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	1,858	3,195
Inventories	-3,490	-11,036
Prepaid expenses and other	-404	-601
Accounts payable and accrued liabilities	1,155	-6,812
Net cash provided by (used in) operating activities	7,300	-5,614
Cash flows from investing activities:
Additions to property, plant and equipment	-2,903	-968
Acquisition of business, net of cash acquired	-3,239
Acquisition of intangible and other assets	-930	858
Purchases of marketable securities		-4,962
Proceeds from sale or maturity of marketable securities	303	7,365
Net cash (used in) provided by investing activities	-6,769	2,293
Cash flows from financing activities:
Repayment of long-term debt		-1,875
Payment of contingent consideration previously established in purchase accounting	-950
Proceeds from exercise of stock options and employee stock purchase plan	678	579
Net cash used in financing activities	-272	-1,296
Effect of exchange rate changes on cash and cash equivalents	4	5
Increase (Decrease) in cash and cash equivalents	263	-4,612
Cash and cash equivalents at beginning of period	21,802	23,508
Cash and cash equivalents at end of period	22,065	18,896
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of intangibles and business	4,970
Contractual obligations for acquisition of fixed assets		$2,769

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
In Thousands, except Share data
Beginning Balance at May. 31, 2013	$526,830	$351	$500,554	$29,563	($1,534)	($2,104)
Beginning Balance, Shares at May. 31, 2013		35,060,351				-142,305
Net loss	-426			-426
Exercise of stock options	11		11
Exercise of stock options, Shares		5,273
Tax impact of stock option activity	-61		-61
Purchase of common stock under ESPP	667		667
Purchase of common stock under ESPP, Shares		71,989
Issuance of performance shares	1	1
Issuance of performance shares, Shares		92,820
Stock based compensation	1,152		1,152
Other comprehensive income, net of tax	271				271
Ending Balance at Aug. 31, 2013	$528,445	$352	$502,323	$29,137	($1,263)	($2,104)
Ending Balance, Shares at Aug. 31, 2013		35,230,433				-142,305

Consolidated_Financial_Stateme

Consolidated Financial Statements	3 Months Ended
	Aug. 31, 2013
Accounting Policies [Abstract]
Consolidated Financial Statements	NOTE A – CONSOLIDATED FINANCIAL STATEMENTS
	The consolidated balance sheet as of August 31, 2013, the consolidated statement of stockholders’ equity for the three months ended August 31, 2013, the consolidated statements of income, the consolidated statements of comprehensive income and the consolidated statement of cash flows for the three months ended August 31, 2013 and August 31, 2012 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2013 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2013 (and for all periods presented) have been made.
	Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 31, 2013, filed by us on August 14, 2013. Our most significant accounting policies are disclosed in Note A to the consolidated financial statements included in the aforementioned Form 10-K for the fiscal year ended May 31, 2013. The results of operations in the fiscal periods ended August 31, 2013 and August 31, 2012 are not necessarily indicative of the operating results for the respective full fiscal years.
	The unaudited interim consolidated financial statements for the three months ended August 31, 2013 and August 31, 2012 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, RITA Medical Systems, LLC, AngioDynamics UK Limited, AngioDynamics Netherlands B.V., NM Holding Company, Inc. (Navilyst), Vortex Medical, Inc. since October 15, 2012 and Clinical Devices B.V. since August 15, 2013, (collectively, the “Company”). All intercompany balances and transactions have been eliminated.
	We consider our business to be a single segment entity – the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting in to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources
	We have performed an evaluation of subsequent events through the date the financial statements were issued. See Note N for subsequent event information.
	Recent Developments
	New Credit Agreement
	On September 19, 2013, we refinanced our existing debt by entering into a credit agreement providing for a $100 million senior secured term loan facility and a $100 million senior secured revolving credit facility. On the same date, we repaid all amounts owed under our previously existing credit agreement. See Note N for further information.
	Acquisition of Clinical Devices, B.V.
	On August 15, 2013 we acquired all the outstanding shares of stock of Clinical Devices, B.V., our exclusive distributor of our fluid management products in the Netherlands. The acquisition includes certain in-process research and development for a next-generation tip location technology. See Note B for further information on the acquisition.
	Regulatory Matters
	On May 27, 2011, we received a Warning Letter from FDA in connection with its inspection of our Queensbury, NY manufacturing facility. In the Warning Letter, FDA cited deficiencies in the response letter we provided FDA pertaining to the inspection that occurred from January 4 to January 13, 2011. The deficiencies related to our internal procedures for medical device reporting, corrections and removals and complaint handling. We responded to the Warning Letter and completed corrective and preventive actions to address the observations noted.
	In December 2011, we initiated a comprehensive Quality Call to Action Program to review and augment our Quality Management Systems at our Queensbury facility. To accelerate implementation of the program, we engaged a team of external regulatory and quality experts and reallocated a significant number of engineering and product development resources to support this corporate initiative. From inception of the Quality Call to Action Program through fiscal 2013, we incurred $3.2 million in direct costs associated with the program.
	On February 10, 2012, we received from FDA a Form 483, List of Investigational Observations, in connection with its inspection of our Queensbury facility from November 14, 2011 to February 10, 2012. The Form 483 contained 12 observations related to, among other things, our CAPA (Corrective and Preventive Action) system, MDR (Medical Device Reporting), complaint investigation, corrections and removals, acceptance criteria and training. Some of the observations contained in the Form 483 were repeat observations from the May 27, 2011 Warning Letter.
	On February 13, 2012, we received from FDA a Form 483 in connection with its inspection of our Fremont facility from January 12, 2012 to February 13, 2012. The Form 483 contained six observations related to, among other things, our CAPA system, design controls, risk management and training. We provided responses to FDA within 15 business days of our receipt of the Form 483s.
	On September 24, 2012, we received from FDA a Form 483 in connection with its subsequent inspection of our Queensbury, NY facility from September 6 to September 14, and September 19 to September 24. This re-inspection followed our response to the original Form 483 issued by FDA on February 13, 2012. The Form 483 contained 5 observations related to 510(k) decisions, complaint investigations, acceptance criteria, corrective and preventive actions and training. All but one of the observations in the Form 483 related to events that occurred before the date that we had indicated to FDA in our previous responses that our corrective and remediation activities related to our Quality Call to Action would be completed. We provided responses to FDA within 15 business days of our receipt of the Form 483.
	On November 28, 2012, FDA completed an inspection of our Manchester, GA facility and no Form 483 observations were issued.
	In June 2013, we received approval from FDA to conduct a clinical trial to study the use of the NanoKnife in the treatment of focal prostate cancer. We are moving forward with institutional review board (IRB) submissions and anticipate commencing patient enrollment during our second quarter of fiscal 2014, which ends November 30, 2013.
	We will continue to work closely with FDA to resolve any outstanding issues. Unless the items raised in the previously disclosed Warning Letters and Form 483s are corrected to FDA’s satisfaction or we come to some other arrangement with FDA finally resolving such matters, we may be subject to additional regulatory or legal action, including the issuance of warning letters, injunction, seizure or recall of products, imposition of fines or penalties or operating restrictions on our facilities. Such actions could significantly disrupt our ongoing business and operations and have a material adverse impact on our financial position and operating results.
	Acquisition, restructuring and other items, net
	Navilyst Acquisition Costs
	The three month periods ended August 31, 2013 and August 31, 2012 included approximately $1.2 million and $2.2 million, respectively, in transaction and severance costs related to the Navilyst acquisition. These costs are included in “Acquisition, restructuring and other items, net” in the statements of income. See Note B for additional information.

Acquisitions

Acquisitions	3 Months Ended
	Aug. 31, 2013
Business Combinations [Abstract]
Acquisitions	NOTE B – ACQUISITIONS
	Acquisition of Clinical Devices
	On August 15, 2013 we acquired all the outstanding shares of capital stock of Clinical Devices, B.V., exclusive distributor of our fluid management products in the Netherlands. The stock purchase agreement provided for the payment of $3.7 million in cash at closing, which was subject to a working capital adjustment and $400,000 holdback, plus future earn out consideration payable in cash. Earn out consideration is based on our net sales of the fluid management products during the five quarters following the closing as well as milestone payments for achieving regulatory approvals of certain in process research and development for a next-generation tip location technology. The total estimated purchase consideration of $8.7 million includes the upfront payment and the estimated fair value of contingent consideration of $5.0 million. See Note J for additional information related to the contingent Earn out liability.
	Goodwill recorded as a result of the acquisition was approximately $4.3 million. Goodwill is not deductible for tax purposes. Intangible assets acquired, other than goodwill, totaled approximately $5.1 million, of which $3.6 million has been identified for in-process research and development (10-year estimated weighted average useful life), $1.4 million as customer relationships (15-year estimated weighted average useful life) and $70,000 as trademarks (5-year estimated weighted average useful life). A deferred tax liability of $1.2 million was also recorded.
	The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective August 15, 2013. The pro-forma effects of the acquisition on our income statement and balance sheet were not material. We have not finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date becomes available.
	Acquisition of Microsulis Medical Ltd.
	On March 22, 2012, we established a strategic relationship with Microsulis Medical Ltd. (“Microsulis”), a U.K.-based company specializing in minimally-invasive, microwave ablation technology for the coagulation of soft tissue.
	The relationship included an initial $5 million investment in Microsulis through the purchase of senior preferred stock, representing a 14.3% ownership position, exclusive distribution rights to market and sell their microwave ablation systems in all markets outside the United States from May 2012 through December 2013, and an exclusive option to purchase at any time until September 22, 2013, substantially all of the global assets of Microsulis Medical, Ltd.
	On February 1, 2013, we completed the acquisition of certain assets of Microsulis, which we have accounted for as a business combination, for cash payments at closing totaling $10.0 million, which is subject to a working capital adjustment, a $5.0 million payment due on December 31, 2013 and potential additional cash consideration payable upon performance over the next nine years. We also assumed $1.6 million of liabilities.
	The total estimated purchase consideration of $33.6 million includes the initial investment of $5.0 million, closing payments totaling $10.5 million, a $5.0 million payment due on December 31, 2013 and the estimated fair value of contingent consideration (Earn out) of $13.2 million. The estimated fair value of contingent consideration is based on projected net sales over the nine year period following the closing. The amount of the Earn out consideration that could be paid on net sales is not limited. See Note J for additional information related to the contingent Earn out liability.
	The Microsulis historical financial results were not significant and therefore pro forma results would not be substantially different. The operations of Microsulis have been fully integrated from the date of acquisition.
	The following table summarizes the preliminary estimated fair value of the assets acquired and liabilities assumed (in thousands):
	Accounts receivable	$	364
	Inventories		687
	Other current assets		443
	Fixed assets		1,906
	Intangibles		12,500
	Goodwill		19,284
	Total assets acquired		35,184
	Liabilities assumed		(1,634	)
	Total purchase price	$	33,550
	Cash payment at closing	$	10,566
	Cash payment for initial investment		5,000
	Present value of deferred payment		4,820
	Present value of contingent consideration liability		13,164
	Total purchase price	$	33,550
	The estimated purchase consideration exceeds the fair value of the acquired net assets by $19.3 million and was recorded as goodwill. Goodwill is deductible for tax purposes. Intangible assets are being amortized over their estimated useful lives of which range from 10 to 15 years. During the first fiscal quarter of 2014, we incurred acquisition related costs of $59 thousand, which were expensed to “Acquisition, restructuring and other items, net” in the statement of income.
	Acquisition of Vortex Medical, Inc.
	On October 15, 2012, we acquired all the outstanding capital stock of Vortex Medical, Inc., a privately-held company focused on the development and commercialization of medical devices for venous drainage and the removal of thrombus, or blood clots, from occluded blood vessels. Vortex’s principal product is the AngioVac ® system, which includes the AngioVac Cannula and Circuit. The AngioVac Cannula has a proprietary balloon-actuated, expandable, funnel-shaped distal tip that enhances flow, prevents clogging of the cannula and facilitates en bloc, or whole removal of undesirable intravascular material. Both the AngioVac Cannula and Circuit are FDA-cleared for use during extracorporeal bypass for up to 6 hours. An application for CE Mark approval has been filed.
	The stock purchase agreement provided for the payment of $15.1 million in cash at closing, which was subject to a working capital adjustment, plus future earn out consideration payable in cash. Earn out consideration is based on our net sales of the AngioVac system during the ten years following the closing, payable in the amount of 10% of annual net sales up to $150 million, 12.5% of annual net sales between $150 million and $500 million, and 15% of annual net sales above $500 million. The Earn out consideration is subject to guaranteed minimum payments payable on the anniversary dates following closing, in the amounts of $8.35 million on the first, $8.0 million on the second, third and fourth, and $7.65 million on the fifth anniversary date. If a minimum payment for a period exceeds the contingent earn out payment for the same period, the amount of the excess will be credited against future contingent earn out payments.
	The total estimated purchase consideration of $75.3 million included the upfront payment of $15.1 million and the estimated fair value of contingent consideration of $60.3 million, $40 million of which is guaranteed. The estimated fair value of contingent consideration is based on projected AngioVac net sales in the ten year period following the closing. The amount of the Earn out consideration that could be paid on AngioVac net sales is not limited. See Note J for additional information related to the contingent Earn out liability.
	The Vortex historical financial results were not significant and therefore pro forma results would not be substantially different. The operations of Vortex have been fully integrated from the date of acquisition.
	The following table summarizes the fair value of the assets acquired and liabilities assumed (in thousands):
	Cash and cash equivalents	$	339
	Accounts receivable		203
	Inventories		488
	Other assets		7
	Deferred tax assets		1,307
	Intangibles		72,430
	Goodwill		29,519
	Total assets acquired		104,293
	Deferred tax liabilities		(28,340	)
	Liabilities assumed		(661	)
	Total purchase price	$	75,292
	Cash payments at closing	$	15,105
	Present value of contingent consideration liability		60,302
	Working capital adjustment		(115	)
	Total purchase price	$	75,292
	The purchase consideration exceeded the fair value of the acquired net assets by $29.5 million and was recorded as goodwill. Goodwill is not deductible for tax purposes. Core technologies are being amortized over their estimated useful lives of approximately 15 years as revenues are earned from the sales of the related products.
	Acquisition of Navilyst
	On May, 22, 2012, we completed the acquisition of privately-held Navilyst, a global medical device company with strengths in the vascular access, interventional radiology and interventional cardiology markets. The acquisition and related transaction costs were financed through the issuance of approximately 9.5 million shares of our common stock, $150 million in drawn acquisition debt financing and $97 million of cash. Based on the closing price of our stock of $12.44 on the day prior to the transaction, the purchase price was approximately $361 million.
	The fiscal quarters ended August 31, 2013 and 2012 included $1.2 million and $2.2 million, respectively, in transaction, integration and severance costs related to the Navilyst acquisition. These costs are included in “Acquisition, restructuring and other items, net” in the statement of income. Investment funds affiliated with Avista Capital Partners, former owners of Navilyst, received approximately 9.4 million shares of our common stock and, as of August 31, 2013, held approximately 27% of our outstanding shares. Investment funds affiliated with Avista Capital Partners entered into a stockholders agreement with us as part of the transaction and also appointed two additional directors to our existing Board of Directors.
	To satisfy any working capital adjustment and potential indemnification claims that may arise, $19.1 million of purchase consideration was held in escrow at May 31, 2013, including approximately $14.0 million in cash and approximately 415 thousand shares of common stock. The indemnification claims period terminated on July 15, 2013and the escrow was released.
	Goodwill recorded as a result of the acquisition was $144.7 million. Intangible assets acquired, other than goodwill, totaled approximately $107.1 million, of which $49.4 million has been identified as customer relationships (15-year weighted average useful life), $32.5 million of trademarks (of which $28.6 million has been determined to have an indefinite useful life and the remaining $3.9 million has a 7 year weighted average useful life), $15.1 million of in-process research and development (indefinite useful life until completed) and $10.1 million of technology (6-year weighted average useful life).
	The IPR&D assets, which were accounted for as indefinite-lived assets at the time of acquisition, represent the development of a biomedical polymer additive for use in PICC and other vascular access product lines and a power injectable port which are valued at $12.1 million and $3.0 million, respectively. The biomedical polymer additive product recently received regulatory approval and the product was released in the United States in October 2012 and is being amortized over a 10 year useful life. The power injectable port is expected to be released in the United States in fiscal 2014, subject to regulatory approvals. The fair value of these intangible assets was determined based upon the present value of expected future cash flows adjusted for the probability of technological and commercial risk, utilizing a risk-adjusted discount rate.
	The following table summarizes the fair values of the assets acquired and liabilities assumed (in thousands):
		May 22,
		2012
	Cash and cash equivalents	$	7,683
	Accounts receivable		19,069
	Inventories		26,851
	Prepaid expenses and other current assets		5,504
	Property, plant and equipment		34,017
	Deferred tax assets		34,209
Goodwill		144,705
Intangibles		107,100
Other long-term assets		497
Total assets acquired		379,635
Liabilities assumed		(18,287	)
Total net assets acquired	$	361,348
See Note D for additional information about changes in the carrying amount of goodwill.

Inventories

Inventories	3 Months Ended
	Aug. 31, 2013
Inventory Disclosure [Abstract]
Inventories	NOTE C – INVENTORIES
	Inventories are stated at lower of cost (at standard cost which approximates the first-in, first-out method) or market. Inventories consist of the following:
		Aug 31,		May 31,
		2013		2013
		(in thousands)
	Raw materials	$	21,760	$	18,362
	Work in process		11,871		11,006
	Finished goods		25,618		25,694
	Inventories	$	59,249	$	55,062

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Aug. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE D – GOODWILL AND INTANGIBLE ASSETS
	Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between three and fifteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Our determination of impairment is based on estimates of future cash flows. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
	Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs. Allocated costs were based on respective fair market values at the date of acquisition.
	For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows.
	We consider our business to be a single operating segment entity – the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. For the purpose of assessing goodwill for impairment, we have also determined that there is one reporting unit.
	To determine fair value of our reporting unit, we considered two market-based approaches and an income approach. Under the market-based approaches, we utilized information regarding our own as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We determined the discounted cash flow as the best indicator to determine fair value.
	Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. Solely for purposes of establishing inputs for the fair value calculations, we assumed that the current economic conditions would continue through fiscal year 2014, followed by a recovery thereafter. In addition, we applied gross margin assumptions consistent with our historical trends at various revenue levels and used an EBITDA exit multiple of 6.0 to calculate the terminal value of the reporting unit. In addition, we used a discount rate of 13.5% to calculate the fair value of our reporting unit.
	We completed our annual goodwill impairment test as of December 31, 2012. At December 31, 2012, our reporting unit is the same as our reportable segment. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 5%. The fair value of the reporting unit was reconciled to our current stock market capitalization plus an estimated control premium of approximately 60% as of December 31, 2012.
	Since early November 2008, our stock market capitalization has at times been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2014 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value.
	We also completed our annual indefinite lived asset (NAMIC trademark) test as of December 31, 2012 using the income approach to determine fair value. Our assessment of the NAMIC trademark indicated that the fair value exceeded the carrying value and therefore the asset was not impaired.
	Even though we determined that there was no goodwill impairment as of December 31, 2012, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2013.
	It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.
	Adjustments to goodwill for the three months ended August 31, 2013 are as follows (in thousands):
	Balance, May 31, 2013	$	355,458
	Acquisition of Clinical Devices B.V.		4,278
	Balance, August 31, 2013	$	359,736
	The above change in the carrying value of goodwill is the result of the acquisition of Clinical Devices, B.V. as discussed in Note B.
	The balances of intangible assets are as follows:
		August 31, 2013
		Gross							Weighted
		carrying		Accumulated			Net carrying		avg useful
		value		amortization			value		life
				(in thousands)					(years)
	Product technologies	$	149,105	$	(26,625	)	$	122,480		10.3
	Customer relationships		86,598		(32,572	)		54,026		11.9
	Trademark-NAMIC		28,600		—			28,600		Indefinite
	Licenses		7,388		(4,819	)		2,569		7.7
	Trademarks		6,345		(1,265	)		5,080		8
	In-process R&D acquired		3,600		—			3,600		Indefinite
	Distributor relationships		900		(900	)		—		3
		$	282,536	$	(66,181	)	$	216,355
		May 31, 2013
		Gross							Weighted
		carrying		Accumulated			Net carrying		avg useful
		value		amortization			value		life
				(in thousands)					(years)
	Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
	Customer relationships		84,479		(30,595	)		53,884		14.8
	Trademark-NAMIC		28,600		—			28,600		Indefinite
	Licenses		6,302		(4,501	)		1,801		9
	Trademarks		6,275		(1,058	)		5,217		9.9
	Distributor relationships		900		(900	)		—		3
		$	276,737	$	(61,889	)	$	214,848

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Aug. 31, 2013
Payables And Accruals [Abstract]
Accrued Liabilities	NOTE E – ACCRUED LIABILITIES
	Accrued liabilities consist of the following:
		Aug 31,		May 31,
		2013		2013
		(in thousands)
	Payroll and related expenses	$	6,815	$	6,491
	Royalties		1,870		2,034
	Deferred revenue		1,590		1,573
	Accrued severance		1,363		1,602
	Sales and franchise taxes		1,165		1,047
	Interest rate swap liability		203		523
	Other		3,493		3,156
	Total	$	16,499	$	16,426
	Our operating results include additional expense of approximately $0.3 million for accrual balances that were estimated at May 31, 2013 and corrected during the quarter ended August 31, 2013 for their final settlement amount. The amount is deemed immaterial to the previously issued financial statements and to the current period financial statements.

Long_Term_Debt

Long Term Debt	3 Months Ended
	Aug. 31, 2013
Debt Disclosure [Abstract]
Long Term Debt	NOTE F – LONG TERM DEBT
	Bank Credit Agreement
	In connection with the Navilyst acquisition, we entered into a Credit Agreement with a group of banks which provided a $150 million senior secured term loan facility and a $50 million senior secured revolving credit facility. The $150 million in proceeds from the term loan were used to finance a portion of the consideration for the acquisition. The revolving facility may be used for general corporate purposes and was undrawn at August 31, 2013. Both facilities have five year maturities. The term facility has a quarterly repayment schedule equal to 5%, 5%, 15%, 25% and 50% of its principal amount in years one through five. The credit agreement contains certain financial covenants relating to fixed charge coverage and leverage, as defined, with which we were in compliance at August 31, 2013. Amounts borrowed under the Credit Agreement are collateralized by all our assets. Interest on both the term loan and the revolving loan is based on a base rate or Eurodollar rate plus an applicable margin with increases as our total leverage ratio increases, and with the base rate and Eurodollar rate have ranges of 1.0% to 1.75% and 2.0% to 2.75% respectively. In the event of default, the interest rate may be increased by 2.0%. The revolving facility will also carry a commitment fee of 0.30% to 0.50% per year on the unused portion. As of August 31, 2013, net deferred financing costs of $1.83 million are recorded as a component of other assets on the balance sheet and are being amortized over the remaining life of the related debt.
	In June 2012, we entered in an interest rate swap agreement, with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualifies for hedge accounting under authoritative guidance, is a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement.
	The Credit Agreement includes, among other standard provisions, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.75 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not more than the applicable ratios as set forth in the Credit Agreement. We were in compliance with both financial covenants as of August 31, 2013.
	On September 19, 2013, we refinanced our bank credit facility. See Note N for subsequent event information.

Income_Taxes

Income Taxes	3 Months Ended
	Aug. 31, 2013
Income Tax Disclosure [Abstract]
Income Taxes	NOTE G – INCOME TAXES
	Our effective tax rate was a 34% benefit for the first fiscal quarter of 2014 compared with 38% benefit for the prior year period. The current quarter reflects a seven month benefit from the R&D tax credit that is due to expire on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible interest expense related to contingent payments. The prior year quarter reflects that the R&D tax credit which expired December 31, 2011 was not renewed until the third quarter of 2013.

Earnings_Per_Common_Share

Earnings Per Common Share	3 Months Ended
	Aug. 31, 2013
Earnings Per Share [Abstract]
Earnings Per Common Share	NOTE H – EARNINGS PER COMMON SHARE
	Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share further includes the dilutive effect of potential common stock consisting of stock options, warrants, and restricted stock units, provided that the inclusion of such securities is not antidilutive. Due to a reported net loss for the first fiscal quarter of both 2014 and 2013, our basic and diluted earnings per share calculations are identical.
	The following table sets forth the reconciliation of the weighted-average number of common shares (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Basic		34,950		34,704
	Effect of dilutive securities		0		0
	Diluted		34,950		34,704
	Excluded from the calculation of diluted earnings per common share were options and restricted stock awards issued to employees and non-employees to purchase 2.8 million shares of common stock for the three months ended August 31, 2013, as their inclusion would be antidilutive. For the comparable three month period ended August 31, 2012, options and restricted stock awards issued to employees and non-employees to purchase 2.9 million shares of common stock were also excluded as their inclusion would be antidilutive.

Segment_and_Geographic_Informa

Segment and Geographic Information	3 Months Ended
	Aug. 31, 2013
Segment Reporting [Abstract]
Segment and Geographic Information	NOTE I – SEGMENT AND GEOGRAPHIC INFORMATION
	We consider our business to be a single operating segment entity – the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting in to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
	Net sales by product category are summarized below (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Net sales
	Peripheral Vascular	$	45,481	$	43,243
	Vascular Access		25,282		26,584
	Oncology/Surgery		11,167		11,321
	Supply Agreement		1,649		2,258
	Total	$	83,579	$	83,406
	Net sales for geographic areas, based on external customer location, are summarized below (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Net Sales
	United States	$	67,102	$	65,593
	International		14,828		15,555
	Supply Agreement		1,649		2,258
	Total	$	83,579	$	83,406

Fair_Value

Fair Value	3 Months Ended
	Aug. 31, 2013
Fair Value Disclosures [Abstract]
Fair Value	NOTE J – FAIR VALUE
	Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs related to the acquisition of Vortex and Microsulis. The carrying amount of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the immediate or short-term maturities. The interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. Marketable securities, with the exception of auction rate securities, are carried at their fair value as determined by quoted market prices. The contingent earn out has been recorded at fair value using the income approach.
	Per our accounting policy, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.
	Level 1	Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.
	Level 2	Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.
	Level 3	Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently includes the auction rate securities where independent pricing information was not able to be obtained and the contingent Earn out related to the acquisition of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities. The contingent earn outs were valued utilizing a discounted cash flow method as detailed below.
	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):
		Fair Value Measurements using inputs
		considered as:								Fair Value at
										August 31,
		Level 1			Level 2			Level 3		2013
	Financial Assets
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,850	$	1,850
	Total Financial Assets	$	—		$	—		$	1,850	$	1,850
	Financial Liabilities
	Interest rate swap agreements	$	—		$	203		$	—	$	203
	Contingent liability for acquisition earn out		—			—			79,800		79,800
	Total Financial Liabilities	$	—		$	203		$	79,800	$	80,003
		Fair Value Measurements using inputs								Fair Value at
		considered as:								May 31,
		Level 1			Level 2			Level 3		2013
	Financial Assets
	Cash equivalents
	Money market funds	$	114		$	—		$	—	$	114
	Total	$	114		$	—		$	—	$	114
	Marketable securities
	Corporate bond securities	$	—		$	303		$	—	$	303
	U.S. government agency obligations		—			—			1,850		1,850
	Total		—			303			1,850		2,153
	Total Financial Assets	$	114		$	303		$	1,850	$	2,267
	Financial Liabilities
	Interest rate swap agreements	$	—		$	522		$	—	$	522
	Contingent liability for acquisition earn out								75,049		75,049
	Total Financial Liabilities	$	—		$	522		$	75,049	$	75,571
	There were no significant transfers in and out of Level 1, 2 and 3 measurements for the three months ended August 31, 2013.
	The components of Level 3 fair value instruments as of August 31, 2013 are shown below (in thousands):
		Financial Assets			Financial Liabilities
		Fair Value Measurements			Fair Value Measurements
		Using Significant			Using Significant
		Unobservable Inputs			Unobservable Inputs
		(Level 3)			(Level 3)
	Balance, May 31, 2013	$	1,850		$	75,049
	Total gains or losses (realized/unrealized):		—			—
	Included in earnings		—			733
	Included in other comprehensive income		—			—
	Purchases, issuances and settlements		—			(950	)
	Transfers in and/or (out) of Level 3		—			—
	Contingent consideration - Clinical Devices		—			4,968
	Balance, August 31, 2013	$	1,850		$	79,800
	Contingent Liability for Acquisition Earn Outs
	Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. Contingent consideration is recorded at the estimated fair value of the contingent milestone payments on the acquisition date for all acquisitions subsequent to April 24, 2009. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within acquisition-related items in the condensed consolidated statements of earnings. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.
	Contingent consideration liabilities will be remeasured to fair value each reporting period using projected net sales, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases in projected net sales and probabilities of payment may result in higher fair value measurements in the future. Increases in discount rates and the projected time to payment may result in lower fair value measurements in the future. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
	The recurring Level 3 fair value measurements of the contingent consideration liability related to the Vortex, Microsulis and Clinical Devices acquisitions include the following significant unobservable inputs ($ in millions):
		Fair value at			Valuation		Unobservable
		Aug 31, 2013			Technique		Input	Range
	Revenue based payments	$	75.7		Discounted		Discount rate	4%-10%
					cash flow		Probability of payment	75-100%
							Projected fiscal year of payment	2014 - 2022
	Milestone based payments		4.1		Discounted		Discount rate	16%-20%
					cash flow		Probability of payment	75-100%
							Projected fiscal year of payment	2014 - 2015
	Total	$	79.8
	At August 31, 2013, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $94.3 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2014 to 2022 in order for the consideration to be paid.
The fair value of contingent milestone payments associated with the acquisitions was remeasured as of August 31, 2013 and $12.7 million was reflected in “Contingent consideration, net of current portion” and $67.1 million was reflected in “Current portion of contingent consideration” on the condensed consolidated balance sheet.
The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments associated with the Vortex and Microsulis acquisitions measured at fair value that used significant unobservable inputs (Level 3) (in thousands):
Beginning balance - May 31, 2013	$	75.0
Purchase price contingent consideration		5
Contingent payments		(1.0	)
Change in fair value of contingent consideration		0.7
Ending balance - August 31, 2013	$	79.8

Marketable_Securities

Marketable Securities	3 Months Ended
	Aug. 31, 2013
Investments Debt And Equity Securities [Abstract]
Marketable Securities	NOTE K – MARKETABLE SECURITIES
	Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of August 31, 2013 and May 31, 2013, we had $1.85 million in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities.
	Marketable securities as of August 31, 2013 consisted of the following:
				Gross		Gross
		Amortized		Unrealized		Unrealized
		cost		Gains		Losses		Fair Value
		(in thousands)
	Available-for-sales securities
	U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
		$	1,850	$	—	$	—	$	1,850
	Marketable securities as of May 31, 2013 consisted of the following:
				Gross		Gross
		Amortized		Unrealized		Unrealized
		cost		Gains		Losses		Fair Value
		(in thousands)
	Available-for-sales securities
	U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
	Corporate bond securities		303		—		—		303
		$	2,153	$	—	$	—	$	2,153

Litigation

Litigation	3 Months Ended
	Aug. 31, 2013
Commitments And Contingencies Disclosure [Abstract]
Litigation	NOTE L – LITIGATION
	AngioDynamics v. biolitec
	On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we are seeking judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court for the Northern District of New York granted key portions of our motion for summary judgment in our legal case against biolitec. The Court’s order was filed under seal. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million.
	In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. This case is currently in the discovery phase. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction.
	We will continue to vigorously enforce our rights under the supply agreement with biolitec.
	C.R. Bard, Inc. v. AngioDynamics, Inc.
	On January 11, 2012, C.R. Bard, Inc. filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on patents held by Bard. Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but has asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. We filed petitions for reexamination in the US Patent and Trademark Office which seek to invalidate all three patents asserted in the litigation. Our petitions have been granted and 40 of 41 patent claims have been and remain rejected. The reexamination proceedings are on-going. The case has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
	Cardinal Health v. Navilyst Medical, Inc.
	On December 21, 2011, Cardinal Health Canada 204, Inc. (Cardinal Health) filed a demand for arbitration pursuant to the terms of the International Distributorship Agreement entered into as of November 1, 2008 between Navilyst and Cardinal Health. Cardinal Health claims that it is entitled to damages based on Navilyst’s decision to terminate the International Distributorship Agreement. On September 27, 2013, the parties agreed to a Stipulation of Dismissal With Prejudice, and the case is now terminated.
	Joseph Pierre v. AngioDynamics, Inc.
	In July 2011, a former employee dual-filed a complaint with the New York State Division of Human Rights and the Equal Employment Opportunity Commission, entitled Joseph Pierre v. AngioDynamics, Inc. In this action, the former employee is alleging discrimination due to his status as an African-American, in light of him being reassigned to another project. At the conclusion of its investigation, the Division issued a finding of “no probable cause” on January 6, 2012 and dismissed the complaint. The complainant did not appeal the decision to preserve his New York Human Rights Law claims. On February 22, 2012, the Equal Employment Opportunity Commission issued its determination adopting the decision of the Division and dismissing the charge. The complainant filed a federal claim following the EEOC’s decision in the United States District Court for the Northern District of New York on May 21, 2012. This complaint makes the same allegations of discrimination, and alleges causes of action under Title VII of the Civil Rights Act and 42 U.S.C. 1981. We believe these claims are without merit but have reached a settlement agreement in principle and will be filing a stipulation of discontinuance with the court once we have fully executed a written settlement agreement. The settlement will have no impact on our financial condition or results of operations.
	We are party to other legal actions that arise in the ordinary course of business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	3 Months Ended
	Aug. 31, 2013
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	NOTE M – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	In December 2011 and January 2013, the FASB issued new accounting guidance related to disclosures on offsetting assets and liabilities on the balance sheet. The newly issued accounting standard requires an entity to disclose both gross and net information about instruments and transactions executed under a master netting, or similar, arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its financial position. This guidance is required to be applied retrospectively and is effective for fiscal years beginning on or after January 1, 2013 (our fiscal year 2014). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
	In February 2013, the FASB expanded the disclosure requirements related to changes in accumulated other comprehensive income (AOCI). The new guidance requires disclosure of the amount of income (or loss) reclassified out of AOCI to each respective line item on the statement of income where net income is presented. The guidance allows disclosure of the reclassification either in the notes to the financial statements or parenthetically on the face of the financial statements. This requirement is effective for reporting periods beginning after December 15, 2012 (fourth quarter of our fiscal year 2013). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
	In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

Subsequent_Events

Subsequent Events	3 Months Ended
	Aug. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	NOTE N – SUBSEQUENT EVENTS
	New Credit Agreement
	On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.
	The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Facility”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Facility, the “Facilities”).
	The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.
	The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolver will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, and with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolver will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion.
	Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors.
	On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant, requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00.
	On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty.

Recently_Issued_Accounting_Pro1

Recently Issued Accounting Pronouncements (Policies)	3 Months Ended
	Aug. 31, 2013
Accounting Changes And Error Corrections [Abstract]
Offsetting Assets and Liabilities	In December 2011 and January 2013, the FASB issued new accounting guidance related to disclosures on offsetting assets and liabilities on the balance sheet. The newly issued accounting standard requires an entity to disclose both gross and net information about instruments and transactions executed under a master netting, or similar, arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its financial position. This guidance is required to be applied retrospectively and is effective for fiscal years beginning on or after January 1, 2013 (our fiscal year 2014). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
Changes in Accumulated Other Comprehensive Income	In February 2013, the FASB expanded the disclosure requirements related to changes in accumulated other comprehensive income (AOCI). The new guidance requires disclosure of the amount of income (or loss) reclassified out of AOCI to each respective line item on the statement of income where net income is presented. The guidance allows disclosure of the reclassification either in the notes to the financial statements or parenthetically on the face of the financial statements. This requirement is effective for reporting periods beginning after December 15, 2012 (fourth quarter of our fiscal year 2013). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
Income Taxes	In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
	Aug. 31, 2013
Microsulis Medical Ltd. [Member]
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary estimated fair value of the assets acquired and liabilities assumed (in thousands):
	Accounts receivable	$	364
	Inventories		687
	Other current assets		443
	Fixed assets		1,906
	Intangibles		12,500
	Goodwill		19,284
	Total assets acquired		35,184
	Liabilities assumed		(1,634	)
	Total purchase price	$	33,550
	Cash payment at closing	$	10,566
	Cash payment for initial investment		5,000
	Present value of deferred payment		4,820
	Present value of contingent consideration liability		13,164
	Total purchase price	$	33,550
Vortex Medical, Inc. [Member]
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair value of the assets acquired and liabilities assumed (in thousands):
	Cash and cash equivalents	$	339
	Accounts receivable		203
	Inventories		488
	Other assets		7
	Deferred tax assets		1,307
	Intangibles		72,430
	Goodwill		29,519
	Total assets acquired		104,293
	Deferred tax liabilities		(28,340	)
	Liabilities assumed		(661	)
	Total purchase price	$	75,292
	Cash payments at closing	$	15,105
	Present value of contingent consideration liability		60,302
	Working capital adjustment		(115	)
	Total purchase price	$	75,292
Navilyst [Member]
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed (in thousands):
		May 22,
		2012
	Cash and cash equivalents	$	7,683
	Accounts receivable		19,069
	Inventories		26,851
	Prepaid expenses and other current assets		5,504
	Property, plant and equipment		34,017
	Deferred tax assets		34,209
	Goodwill		144,705
	Intangibles		107,100
	Other long-term assets		497
	Total assets acquired		379,635
	Liabilities assumed		(18,287	)
	Total net assets acquired	$	361,348

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Aug. 31, 2013
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost (at standard cost which approximates the first-in, first-out method) or market. Inventories consist of the following:
		Aug 31,		May 31,
		2013		2013
		(in thousands)
	Raw materials	$	21,760	$	18,362
	Work in process		11,871		11,006
	Finished goods		25,618		25,694
	Inventories	$	59,249	$	55,062

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Aug. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill by Segment	Adjustments to goodwill for the three months ended August 31, 2013 are as follows (in thousands):
	Balance, May 31, 2013	$	355,458
	Acquisition of Clinical Devices B.V.		4,278
	Balance, August 31, 2013	$	359,736
Intangible Assets	The balances of intangible assets are as follows:
		August 31, 2013
		Gross							Weighted
		carrying		Accumulated			Net carrying		avg useful
		value		amortization			value		life
				(in thousands)					(years)
	Product technologies	$	149,105	$	(26,625	)	$	122,480		10.3
	Customer relationships		86,598		(32,572	)		54,026		11.9
	Trademark-NAMIC		28,600		—			28,600		Indefinite
	Licenses		7,388		(4,819	)		2,569		7.7
	Trademarks		6,345		(1,265	)		5,080		8
	In-process R&D acquired		3,600		—			3,600		Indefinite
	Distributor relationships		900		(900	)		—		3
		$	282,536	$	(66,181	)	$	216,355
		May 31, 2013
		Gross							Weighted
		carrying		Accumulated			Net carrying		avg useful
		value		amortization			value		life
				(in thousands)					(years)
	Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
	Customer relationships		84,479		(30,595	)		53,884		14.8
	Trademark-NAMIC		28,600		—			28,600		Indefinite
	Licenses		6,302		(4,501	)		1,801		9
	Trademarks		6,275		(1,058	)		5,217		9.9
	Distributor relationships		900		(900	)		—		3
		$	276,737	$	(61,889	)	$	214,848

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Aug. 31, 2013
Payables And Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consist of the following:
		Aug 31,		May 31,
		2013		2013
		(in thousands)
	Payroll and related expenses	$	6,815	$	6,491
	Royalties		1,870		2,034
	Deferred revenue		1,590		1,573
	Accrued severance		1,363		1,602
	Sales and franchise taxes		1,165		1,047
	Interest rate swap liability		203		523
	Other		3,493		3,156
	Total	$	16,499	$	16,426

Earnings_Per_Common_Share_Tabl

Earnings Per Common Share (Tables)	3 Months Ended
	Aug. 31, 2013
Earnings Per Share [Abstract]
Reconciliation of Weighted-Average Number of Common Shares	The following table sets forth the reconciliation of the weighted-average number of common shares (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Basic		34,950		34,704
	Effect of dilutive securities		0		0
	Diluted		34,950		34,704

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	3 Months Ended
	Aug. 31, 2013
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	Net sales by product category are summarized below (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Net sales
	Peripheral Vascular	$	45,481	$	43,243
	Vascular Access		25,282		26,584
	Oncology/Surgery		11,167		11,321
	Supply Agreement		1,649		2,258
	Total	$	83,579	$	83,406
Summary of Net Sales for Geographic Areas	Net sales for geographic areas, based on external customer location, are summarized below (in thousands):
		Three Months Ended
		Aug 31,		Aug 31,
		2013		2012
	Net Sales
	United States	$	67,102	$	65,593
	International		14,828		15,555
	Supply Agreement		1,649		2,258
	Total	$	83,579	$	83,406

Fair_Value_Tables

Fair Value (Tables)	3 Months Ended
	Aug. 31, 2013
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):
		Fair Value Measurements using inputs
		considered as:								Fair Value at
										August 31,
		Level 1			Level 2			Level 3		2013
	Financial Assets
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,850	$	1,850
	Total Financial Assets	$	—		$	—		$	1,850	$	1,850
	Financial Liabilities
	Interest rate swap agreements	$	—		$	203		$	—	$	203
	Contingent liability for acquisition earn out		—			—			79,800		79,800
	Total Financial Liabilities	$	—		$	203		$	79,800	$	80,003
		Fair Value Measurements using inputs								Fair Value at
		considered as:								May 31,
		Level 1			Level 2			Level 3		2013
	Financial Assets
	Cash equivalents
	Money market funds	$	114		$	—		$	—	$	114
	Total	$	114		$	—		$	—	$	114
	Marketable securities
	Corporate bond securities	$	—		$	303		$	—	$	303
	U.S. government agency obligations		—			—			1,850		1,850
	Total		—			303			1,850		2,153
	Total Financial Assets	$	114		$	303		$	1,850	$	2,267
	Financial Liabilities
	Interest rate swap agreements	$	—		$	522		$	—	$	522
	Contingent liability for acquisition earn out								75,049		75,049
	Total Financial Liabilities	$	—		$	522		$	75,049	$	75,571
Fair Value Measurements Using Significant Unobservable Inputs	The components of Level 3 fair value instruments as of August 31, 2013 are shown below (in thousands):
		Financial Assets			Financial Liabilities
		Fair Value Measurements			Fair Value Measurements
		Using Significant			Using Significant
		Unobservable Inputs			Unobservable Inputs
		(Level 3)			(Level 3)
	Balance, May 31, 2013	$	1,850		$	75,049
	Total gains or losses (realized/unrealized):		—			—
	Included in earnings		—			733
	Included in other comprehensive income		—			—
	Purchases, issuances and settlements		—			(950	)
	Transfers in and/or (out) of Level 3		—			—
	Contingent consideration - Clinical Devices		—			4,968
	Balance, August 31, 2013	$	1,850		$	79,800
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liability related to the Vortex, Microsulis and Clinical Devices acquisitions include the following significant unobservable inputs ($ in millions):
		Fair value at			Valuation		Unobservable
		Aug 31, 2013			Technique		Input	Range
	Revenue based payments	$	75.7		Discounted		Discount rate	4%-10%
					cash flow		Probability of payment	75-100%
							Projected fiscal year of payment	2014 - 2022
	Milestone based payments		4.1		Discounted		Discount rate	16%-20%
					cash flow		Probability of payment	75-100%
							Projected fiscal year of payment	2014 - 2015
	Total	$	79.8
Summary Showing Reconciliation of the Contingent Payments	The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments associated with the Vortex and Microsulis acquisitions measured at fair value that used significant unobservable inputs (Level 3) (in thousands):
	Beginning balance - May 31, 2013	$	75.0
	Purchase price contingent consideration		5
	Contingent payments		(1.0	)
	Change in fair value of contingent consideration		0.7
	Ending balance - August 31, 2013	$	79.8

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Aug. 31, 2013
Investments Debt And Equity Securities [Abstract]
Marketable Securities	Marketable securities as of August 31, 2013 consisted of the following:
				Gross		Gross
		Amortized		Unrealized		Unrealized
		cost		Gains		Losses		Fair Value
		(in thousands)
	Available-for-sales securities
	U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
		$	1,850	$	—	$	—	$	1,850
	Marketable securities as of May 31, 2013 consisted of the following:
				Gross		Gross
		Amortized		Unrealized		Unrealized
		cost		Gains		Losses		Fair Value
		(in thousands)
	Available-for-sales securities
	U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
	Corporate bond securities		303		—		—		303
		$	2,153	$	—	$	—	$	2,153

Consolidated_Financial_Stateme1

Consolidated Financial Statements - Additional Information (Detail) (USD $)	1 Months Ended				3 Months Ended
In Millions, unless otherwise specified	Nov. 28, 2012	Sep. 24, 2012	Feb. 13, 2012	Feb. 10, 2012	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Sep. 19, 2013	Sep. 19, 2013
	Observations	Observations	Observations	Observations			Clinical Devices B.V. [Member]	Subsequent Event [Member]	Subsequent Event [Member]
								Term Loan Facility [Member]	Senior Secured Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior secured term loan facility					$150			$100	$100
Date of business acquisition							15-Aug-13
Costs for Quality Call to Action Program					3.2
Number of observations	0	5	6	12
Number of business days to provide response to FDA					15 days
Transaction and severance costs related to acquisition					$1.20	$2.20

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)

3 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

Aug. 31, 2013

Aug. 31, 2012

31-May-13

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Feb. 01, 2013

Mar. 22, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

22-May-12

Aug. 31, 2013

Aug. 31, 2012

Aug. 15, 2013

Aug. 31, 2013

22-May-12

22-May-12

Aug. 31, 2013

31-May-13

22-May-12

Aug. 15, 2013

Aug. 31, 2013

31-May-13

22-May-12

Aug. 15, 2013

22-May-12

22-May-12

Aug. 15, 2013

Aug. 31, 2013

22-May-12

Minimum [Member]

Maximum [Member]

Microsulis Medical Ltd. [Member]

Microsulis Medical Ltd. [Member]

Microsulis Medical Ltd. [Member]

Microsulis Medical Ltd. [Member]

Microsulis Medical Ltd. [Member]

Vortex Medical, Inc. [Member]

Navilyst [Member]

Navilyst [Member]

Navilyst [Member]

Clinical Devices B.V. [Member]

Avista Capital Partners [Member]

Biomedical Polymer Additive [Member]

Power Injectable Port [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trademarks [Member]

Trademarks [Member]

Trademarks [Member]

Trademarks [Member]

Trademark-NAMIC [Member]

In-Process Research and Development [Member]

In-Process Research and Development [Member]

Technology [Member]

Technology [Member]

Minimum [Member]

Maximum [Member]

Clinical Devices B.V. [Member]

Clinical Devices B.V. [Member]

Clinical Devices B.V. [Member]

Business Acquisition [Line Items]

Cash payments at closing total

$10,566,000

$10,000,000

$15,105,000

$97,000,000

$3,700,000

Business acquisition purchase price holdback amount

400,000

Total purchase price

33,550,000

75,292,000

361,000,000

8,700,000

Present value of contingent consideration liability

13,164,000

60,302,000

5,000,000

Goodwill acquired

19,284,000

29,519,000

144,705,000

4,300,000

Intangible assets other than goodwill

12,500,000

72,430,000

107,100,000

5,100,000

32,500,000

Acquired finite lived intangible assets

49,400,000

1,400,000

3,900,000

70,000

3,600,000

10,100,000

Weighted average useful life

10 years

15 years

15 years

15 years

7 years

5 years

10 years

6 years

Deferred tax liabilities

28,340,000

1,200,000

Investment in company

5,000,000

Ownership percentage in investment

14.30%

Business acquisition cost of acquired entity purchase price payable

5,000,000

5,000,000

Liabilities assumed

1,634,000

1,600,000

661,000

18,287,000

Additional cash consideration payable period

9 years

Acquisition of related cost

59,000

Percentage of annual net sales, first limit

10.00%

Annual net sales, first limit

150,000,000

Percentage of annual net sales, second limit

12.50%

Annual net sales, second limit

150,000,000

Annual net sales

500,000,000

Percentage of annual net sales, third limit

15.00%

Annual net sales, third limit

500,000,000

Guaranteed minimum payments payable first anniversary

8,350,000

Guaranteed minimum payments payable second anniversary

8,000,000

Guaranteed minimum payments payable third anniversary

8,000,000

Guaranteed minimum payments payable fourth anniversary

8,000,000

Guaranteed minimum payments payable fifth anniversary

7,650,000

Fair value of guaranteed contingent consideration

40,000,000

Weighted average useful life

3 years

15 years

15 years

10 years

11 years 10 months 24 days

14 years 9 months 18 days

8 years

9 years 10 months 24 days

Issuance of common stock

9,500,000

9,400,000

Senior secured term loan facility

150,000,000

150,000,000

Closing price of stock

$12.44

Transaction and severance costs related to acquisition

1,200,000

2,200,000

1,200,000

2,200,000

Common stock, outstanding shares, percentage

27.00%

Purchase consideration placed in escrow

19,100,000

Purchase consideration placed in escrow in cash

14,000,000

Purchase consideration placed in escrow as common stock

415,000

Acquired intangible asset

$12,100,000

$3,000,000

$28,600,000

$15,100,000

Acquisitions_Summary_of_Estima

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Microsulis Medical Ltd) (Detail) (Microsulis Medical Ltd. [Member], USD $)	Aug. 31, 2013	Feb. 01, 2013
In Thousands, unless otherwise specified
Microsulis Medical Ltd. [Member]
Business Acquisition [Line Items]
Accounts receivable	$364
Inventories	687
Other current assets	443
Fixed assets	1,906
Intangibles	12,500
Goodwill	19,284
Total assets acquired	35,184
Liabilities assumed	-1,634	-1,600
Total purchase price	33,550
Cash payment at closing	10,566	10,000
Cash payment for initial investment	5,000
Present value of deferred payment	4,820
Present value of contingent consideration liability	13,164
Total purchase price	$33,550

Acquisitions_Summary_of_Estima1

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Vortex Medical) (Detail) (Vortex Medical, Inc. [Member], USD $)	Aug. 31, 2013
In Thousands, unless otherwise specified
Vortex Medical, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$339
Accounts receivable	203
Inventories	488
Other assets	7
Deferred tax assets	1,307
Intangibles	72,430
Goodwill	29,519
Total assets acquired	104,293
Deferred tax liabilities	-28,340
Liabilities assumed	-661
Total purchase price	75,292
Cash payments at closing	15,105
Present value of contingent consideration liability	60,302
Working capital adjustment	-115
Total purchase price	$75,292

Acquisitions_Summary_of_Estima2

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Navilyst) (Detail) (Navilyst [Member], USD $)	22-May-12
In Thousands, unless otherwise specified
Navilyst [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$7,683
Accounts receivable	19,069
Inventories	26,851
Prepaid expenses and other current assets	5,504
Property, plant and equipment	34,017
Deferred tax assets	34,209
Goodwill	144,705
Intangibles	107,100
Other long-term assets	497
Total assets acquired	379,635
Liabilities assumed	-18,287
Total net assets acquired	$361,348

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Aug. 31, 2013	31-May-13
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$21,760	$18,362
Work in process	11,871	11,006
Finished goods	25,618	25,694
Inventories	$59,249	$55,062

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Aug. 31, 2013
		Segment
		Reporting_Unit
Finite-Lived Intangible Assets [Line Items]
Number of reportable unit		1
Number of operating segment		1
Terminal value of the reporting unit		6
Discount rate used in fair value calculation		13.50%
Percentage of fair value, carrying value	5.00%
Estimated control premium used in fair value calculation	60.00%
Goodwill impairment	$0
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		15 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		3 years

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Goodwill by Segment (Detail) (USD $)	Aug. 31, 2013	31-May-13	Aug. 31, 2013
In Thousands, unless otherwise specified			Clinical Devices B.V. [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	$359,736	$355,458
Acquisition			4,278
Goodwill, Ending Balance	$359,736	$355,458

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	31-May-13
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$282,536	$276,737
Accumulated amortization	-66,181	-61,889
Net carrying value	216,355	214,848
Product Technologies [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	149,105	150,181
Accumulated amortization	-26,625	-24,835
Net carrying value	122,480	125,346
Weighted average useful life	10 years 3 months 18 days	10 years 7 months 6 days
Customer Relationships [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	86,598	84,479
Accumulated amortization	-32,572	-30,595
Net carrying value	54,026	53,884
Weighted average useful life	11 years 10 months 24 days	14 years 9 months 18 days
Licenses [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	7,388	6,302
Accumulated amortization	-4,819	-4,501
Net carrying value	2,569	1,801
Weighted average useful life	7 years 8 months 12 days	9 years
Trademarks [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	6,345	6,275
Accumulated amortization	-1,265	-1,058
Net carrying value	5,080	5,217
Weighted average useful life	8 years	9 years 10 months 24 days
Distributor Relationships [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	900	900
Accumulated amortization	-900	-900
Net carrying value
Weighted average useful life	3 years	3 years
In-Process Research and Development [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	3,600
Net carrying value	3,600
Trademark-NAMIC [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	28,600	28,600
Net carrying value	$28,600	$28,600

Accrued_Liabilities_Summary_of

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $)	Aug. 31, 2013	31-May-13
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$6,815	$6,491
Royalties	1,870	2,034
Deferred revenue	1,590	1,573
Accrued severance	1,363	1,602
Sales and franchise taxes	1,165	1,047
Interest rate swap liability	203	523
Other	3,493	3,156
Total	$16,499	$16,426

Accrued_Liabilities_Additional

Accrued Liabilities - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Aug. 31, 2013
Other Liabilities Disclosure [Abstract]
Additional expense for accrual balances	$0.30

Long_Term_Debt_Additional_Info

Long Term Debt - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Aug. 31, 2013
	Agreement
Debt Instrument [Line Items]
Senior secured term loan facility	$150
Senior secured revolving credit facility	50
Bank credit agreement maturity period	5 Years
Percentage of quarterly repayment of term facility year one	5.00%
Percentage of quarterly repayment of term facility year two	5.00%
Percentage of quarterly repayment of term facility year three	15.00%
Percentage of quarterly repayment of term facility year four	25.00%
Percentage of quarterly repayment of term facility year five	50.00%
Percentage of increase in interest	2.00%
Net deferred financing costs	1.83
Notional amount of interest rate swap agreement	$100
Fixed interest rate payments	0.74%
Number of financial covenants	2
Covenant ratio range	Not less than 1.75 to 1.00
Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.30%
Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.50%
Line of Credit [Member] | Banks [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	2.00%
Percentage of increases leverage ratio base rate, maximum	2.75%
Term Loan [Member] | Banks [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.00%
Percentage of increases leverage ratio base rate, maximum	1.75%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Income Tax Disclosure [Abstract]
Effective income tax rate	34.00%	38.00%

Earnings_Per_Common_Share_Reco

Earnings Per Common Share - Reconciliation of Weighted-Average Number of Common Shares (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Earnings Per Share [Abstract]
Basic	34,950	34,704
Effect of dilutive securities	0	0
Diluted	34,950	34,704

Earnings_Per_Common_Share_Addi

Earnings Per Common Share - Additional Information (Detail)	3 Months Ended
In Millions, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of diluted earnings per share	2.8	2.9

Segment_and_Geographic_Informa2

Segment and Geographic Information - Additional Information (Detail)	3 Months Ended
	Aug. 31, 2013
	Segment
Segment Reporting [Abstract]
Number of segment	1

Segment_and_Geographic_Informa3

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Net Sales by Product Category [Line Items]
Net sales	$83,579	$83,406
Peripheral Vascular [Member]
Net Sales by Product Category [Line Items]
Net sales	45,481	43,243
Vascular Access [Member]
Net Sales by Product Category [Line Items]
Net sales	25,282	26,584
Oncology/Surgery [Member]
Net Sales by Product Category [Line Items]
Net sales	11,167	11,321
Supply Agreement [Member]
Net Sales by Product Category [Line Items]
Net sales	$1,649	$2,258

Segment_and_Geographic_Informa4

Segment and Geographic Information - Summary of Net Sales for Geographic Areas (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Aug. 31, 2012
Net Sales
Net sales	$83,579	$83,406
United States [Member]
Net Sales
Net sales	67,102	65,593
International [Member]
Net Sales
Net sales	14,828	15,555
Supply Agreement [Member]
Net Sales
Net sales	$1,649	$2,258

Fair_Value_Fair_Value_of_Asset

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) (Recurring [Member], USD $)	Aug. 31, 2013	31-May-13
In Thousands, unless otherwise specified
Financial Liabilities
Total Financial Liabilities	$80,003	$75,571
Financial Assets
Cash equivalents		114
Marketable securities		2,153
Total Financial Assets	1,850	2,267
Money Market Funds [Member]
Financial Assets
Cash equivalents		114
Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,850	1,850
Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	203	522
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	79,800	75,049
Level 1 [Member]
Financial Liabilities
Total Financial Liabilities
Financial Assets
Cash equivalents		114
Marketable securities
Total Financial Assets		114
Level 1 [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents		114
Level 1 [Member] | Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 1 [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities
Level 1 [Member] | Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 2 [Member]
Financial Liabilities
Total Financial Liabilities	203	522
Financial Assets
Cash equivalents
Marketable securities		303
Total Financial Assets		303
Level 2 [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 2 [Member] | Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
Level 2 [Member] | Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	203	522
Level 3 [Member]
Financial Liabilities
Total Financial Liabilities	79,800	75,049
Financial Assets
Cash equivalents
Marketable securities		1,850
Total Financial Assets	1,850	1,850
Level 3 [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 3 [Member] | Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 3 [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,850	1,850
Level 3 [Member] | Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 3 [Member] | Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	$79,800	$75,049

Fair_Value_Fair_Value_Measurem

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013
Fair Value Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]
Balance, May 31, 2013, Financial Assets	$1,850
Total gains or losses (realized/unrealized):
Included in earnings, Financial Assets
Included in other comprehensive income, Financial Assets
Purchases, issuances and settlements, Financial Assets
Transfers in and/or (out) of Level 3, Financial Assets
Balance, August 31, 2013, Financial Assets	1,850
Balance, May 31, 2013, Financial Liabilities	75,049
Included in earnings, Financial Liabilities	733
Included in other comprehensive income, Financial Liabilities
Purchases, issuances and settlements, Financial Liabilities	-950
Transfers in and/or (out) of Level 3, Financial Liabilities
Balance, August 31, 2013, Financial Liabilities	79,800
Clinical Devices B.V. [Member]
Total gains or losses (realized/unrealized):
Contingent consideration - Clinical Devices, Financial Assets
Contingent consideration - Clinical Devices, Financial Liabilities	$4,968

Fair_Value_Summary_Showing_the

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) (USD $)	Aug. 31, 2013	31-May-13	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013
In Thousands, unless otherwise specified			Level 3 [Member]	Range One [Member]	Range One [Member]	Range One [Member]	Range Two [Member]	Range Two [Member]	Range Two [Member]
			Contingent Consideration Earn Out Liability [Member]	Level 3 [Member]	Level 3 [Member]	Level 3 [Member]	Level 3 [Member]	Level 3 [Member]	Level 3 [Member]
				Contingent Consideration Earn Out Liability [Member]	Maximum [Member]	Minimum [Member]	Contingent Consideration Earn Out Liability [Member]	Maximum [Member]	Minimum [Member]
				Recurring [Member]	Contingent Consideration Earn Out Liability [Member]	Contingent Consideration Earn Out Liability [Member]	Recurring [Member]	Contingent Consideration Earn Out Liability [Member]	Contingent Consideration Earn Out Liability [Member]
					Recurring [Member]	Recurring [Member]		Recurring [Member]	Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Revenue/Milestone based payments	$79,800	$75,049	$79,800	$75,700			$4,100
Discount rate					10.00%	4.00%		20.00%	16.00%
Probability of payment					100.00%	75.00%		100.00%	75.00%
Projected fiscal year of payment					2022	2014		2015	2014

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (USD $)	Aug. 31, 2013
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$94.30
Fair value of contingent milestone payments, long term portion	12.7
Fair value of contingent milestone payments, current portion	$67.10

Fair_Value_Summary_Showing_Rec

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) (Contingent Consideration Earn Out Liability [Member], Vortex Medical, Inc. [Member], USD $)	3 Months Ended
	Aug. 31, 2013
Contingent Consideration Earn Out Liability [Member] | Vortex Medical, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - May 31, 2013	$75,000
Purchase price contingent consideration	5,000
Contingent payments	-1,000
Change in fair value of contingent consideration	700
Ending balance - August 31, 2013	$79,800

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	Aug. 31, 2013	31-May-13
In Millions, unless otherwise specified	Investment	Investment
Amortized Cost And Fair Value Debt Securities [Abstract]
Investments in auction rate securities that failed auctions	$1.85	$1.85
Number of investments	2	2

Marketable_Securities_Marketab

Marketable Securities - Marketable Securities (Detail) (USD $)	Aug. 31, 2013	31-May-13
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$1,850	$2,153
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	1,850	2,153
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,850	1,850
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	1,850	1,850
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		303
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value		$303

Litigation_Additional_Informat

Litigation - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Nov. 08, 2012	Aug. 31, 2013	Aug. 31, 2013
	Biolitec [Member]	Biolitec [Member]	C.R. Bard, Inc [Member]
		Lawsuits	Petition
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification		2
Partial judgment granted	$23.20
Number of petitions filed for reexamination of patents			3
Number of patent claims rejected			40 of 41 patent

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

3 Months Ended

1 Months Ended

In Millions, unless otherwise specified

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Sep. 19, 2013

Agreement

Minimum [Member]

Maximum [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Agreement

Minimum [Member]

Maximum [Member]

Line of Credit [Member]

Term Loan [Member]

Term Loan Facility [Member]

Senior Secured Revolving Credit Facility [Member]

Letters of Credit [Member]

Swingline Loans [Member]

Revolving Credit Facility [Member]

Jp Morgan Chase [Member]

Jp Morgan Chase [Member]

Subsequent Event [Line Items]

Senior secured term loan facility

$150

$100

$100

$20

$5

$41.40

Percentage of quarterly repayment of term facility year one

5.00%

5.00%

Percentage of quarterly repayment of term facility year two

5.00%

5.00%

Percentage of quarterly repayment of term facility year three

15.00%

10.00%

Percentage of quarterly repayment of term facility year four

25.00%

15.00%

Percentage of quarterly repayment of term facility year five

50.00%

65.00%

Bank credit agreement maturity period

5 Years

In years one through five

Percentage of increases leverage ratio base rate, minimum

1.50%

0.50%

Percentage of increases leverage ratio base rate, maximum

2.25%

1.25%

Percentage of increase in interest

2.00%

2.00%

Commitment fee percentage

0.30%

0.50%

0.20%

0.35%

Number of financial covenants

2

2

Covenant ratio range

Not less than 1.75 to 1.00

Not less than 1.35 to 1.00

Not greater than 3.75 to 1.00